Open AccessP1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL‐102)
Author(s) -
Hamadani M.,
Coleman M.,
Boccia R.,
Duras J.,
Hutchings M.,
Zinzani P. L.,
Cordoba R.,
Oreiro M. B.,
Williams V.,
Stouffs M.,
Langmuir P.,
Sancho J.M.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847284.03476.7b
Subject(s) - obinutuzumab , bendamustine , medicine , rituximab , follicular lymphoma , regimen , refractory (planetary science) , neutropenia , population , oncology , phases of clinical research , gastroenterology , lymphoma , chemotherapy , environmental health , astrobiology , physics